AU
UK
CA
NZ
IND
US
Prime Medicine (NASDAQ:PRME) has unveiled high-impact clinical results for PM359, its investigational autologous hematopoietic stem cell therapy for p47phox chronic granulomatous disease. The data represents the first clinical demonstration of Prime Editing in humans, signaling a potentially transformative step forward for gene-repair technologies.
Ascentage Pharma Group International (NASDAQ:AAPG) announced that regulators in both the United States and Europe have cleared its global registrational Phase III clinical trial of olverembatinib for the first-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study, known as POLARIS-1 (NCT06051409), …
Belite Bio (NASDAQ:BLTE) moved higher on December 01, 2025, even as broader market sentiment remained subdued. The clinical-stage biotechnology company reported new findings from its late-stage trial for tinlarebant, its leading oral therapy candidate for retinal disorders. The stock closed the session with a …
Bausch Health Companies (NYSE:BHC) closed higher on December 01, 2025, rising at a double-digit rate on a day when the broader U.S. market fell. The S&P 500 and Nasdaq Composite ended lower, but Bausch Health moved in the opposite direction. The stock climbed more …
Jaguar Health’s (NASDAQ:JAGX) share price closed at USD 1.28 at the end of November 2025. The stock is down USD 23.97 year-to-date. This reflects a 94.9% fall in 2025.The NASDAQ-100Index has risen 20.1% in the same period. The relative price change stands at -115%. …
Ascendis Pharma A/S (NASDAQ: ASND) reported that the U.S.Food and Drug Administrationhas extended the decision deadline for its investigational therapy, TransCon CNP (Navepegritide), by three months. The new Prescription Drug User Fee Act date is now set for February 28, 2026, instead of the …
Silexion Therapeutics Corp. (NASDAQ:SLXN) has announced an important milestone with the successful completion of toxicology studies for SIL204, a next-generation RNA-silencing therapy developed to target mutated KRAS oncogenes. Pancreatic cancer continues to be one of the deadliest malignancies, with limited treatment choices and exceptionally …
GE HealthCare Technologies, Inc. (NASDAQ:GEHC) has receivedFDAPremarket Authorization for Pristina Recon DL, a next-generation 3D mammography image reconstruction solution. This milestone highlights the company’s continuedinvestmentinAI-driven technologies designed to enhance diagnostic accuracy in breast imaging.
Microbot Medical Inc. (NASDAQ:MBOT) announced that Emory University Hospital in Atlanta is the first hospital worldwide to adopt its LIBERTY® Endovascular Robotic System. LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system designed for peripheral endovascular procedures. It enables precise navigation within vascular …
CollPlant Biotechnologies (NASDAQ:CLGN) reported its third-quarter 2025 financial results, highlighting scientific progress, commercial expansion and ongoing program development. The company’s proprietary non-animal recombinant human collagen (rhCollagen) continues to gain recognition as an ethical, sustainable and high-performance alternative for use across tissue engineering, aesthetics and …
Please wait processing your request...